# EPCORE DLBCL-1: HCP commentary report

> 113 verified statements (39 from clinicians verified by NPI or staff page) from 19 commentary sources · 10 findings · updated Oct 31, 2026

## Report

- Trial: A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
- NCT ID: NCT04628494
- Registry: https://clinicaltrials.gov/study/NCT04628494
- Sponsor: Genmab
- Phase: Phase 3
- Status: Active, not recruiting
- Drugs tested: epcoritamab
- Indication: relapsed/refractory diffuse large B-cell lymphoma
- Version: v1.0.0, edition 1
- Accepted: 2026-10-31
- Last checked: 2026-10-31
- Release hash: bbfa3502fda09cda1febcf229ec16dd7faa0528bebab33c0e24d5f9028b2f206

## Counts

- HCP commentary sources screened: 63
- Sources cited by verified statements: 19
- Verified statements: 113
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 39
- Findings: 10
- Named people in screened sources (unnamed speakers and accounts not counted): 13
- Voices cited: 13
- Cited voices identity-verified: 8
- Organisational or shared accounts (not counted as people): 3

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

EPCORE DLBCL-1 asks whether epcoritamab improves survival over chemotherapy in transplant-ineligible people whose diffuse large B-cell lymphoma has returned or resisted treatment. Commentary comes from X and LinkedIn posts, podcasts and YouTube, including a physician and a medical oncologist. The discussion turns on whether survival and infection findings support trial success, whether chemotherapy is an appropriate comparator and what remains unresolved for regulatory confirmation. The sources reviewed for this edition place its randomized phase 3 results at EHA 2026.

## Open Medical Affairs question

How should durable disease control be discussed alongside infection risk and the absence of a demonstrated survival advantage, while preserving the conditional choice over chemotherapy and the unresolved position relative to CAR-T?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Survival and infection risk constrain the interpretation of success
- F2. The perceived efficacy signal is response durability, not the median PFS difference
- F3. Comparator criticism centers on evolving transplant/CAR-T eligibility and later treatment
- F4. Conditional preference for epcoritamab persists, while combinations and CAR-T positioning remain unsettled
- F5. Cross-trial skepticism is qualified by regimen, line-of-therapy and histology differences
- F6. Off-the-shelf access requires a concrete monitoring and support model
- F7. Earlier use is supported by later-line activity and biological reasoning, not established by those premises
- F8. Sequencing, target reassessment, cure and long-term safety remain open
- F9. Confirmatory and regulatory implications are debated, not announced outcomes
- F10. Development feasibility and nonclinical reactions should remain separate from treatment evidence

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 28 | 14 | 9 | 6 | recorded | 4 |
| F2 | 16 | 13 | 7 | 5 | none recorded | 3 |
| F3 | 8 | 3 | 3 | 2 | recorded | 3 |
| F4 | 17 | 10 | 6 | 4 | recorded | 3 |
| F5 | 6 | 6 | 3 | 5 | recorded | 3 |
| F6 | 13 | 5 | 1 | 1 | none recorded | 3 |
| F7 | 11 | 6 | 3 | 3 | none recorded | 4 |
| F8 | 4 | 2 | 1 | 1 | none recorded | 2 |
| F9 | 11 | 6 | 5 | 4 | recorded | 3 |
| F10 | 6 | 5 | 5 | 5 | none recorded | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 14 | 2 | 0 | 0 | 12 | 34 | 0 | 5 posts and articles, 4 podcasts and video | yes |
| F2 | 7 | 2 | 0 | 2 | 5 | 19 | 1 | 3 posts and articles, 4 podcasts and video | yes |
| F3 | 6 | 1 | 0 | 1 | 0 | 8 | 1 | 1 post or article, 2 podcasts and video | yes |
| F4 | 5 | 3 | 2 | 3 | 4 | 21 | 2 | 2 posts and articles, 4 podcasts and video | yes |
| F5 | 4 | 0 | 0 | 2 | 0 | 6 | 0 | 3 posts and articles | yes |
| F6 | 3 | 0 | 0 | 0 | 10 | 14 | 0 | 1 podcast or video | yes |
| F7 | 4 | 0 | 0 | 0 | 7 | 12 | 3 | 2 posts and articles, 1 podcast or video | yes |
| F8 | 1 | 3 | 0 | 0 | 0 | 4 | 0 | 1 podcast or video | yes |
| F9 | 5 | 0 | 0 | 0 | 6 | 14 | 0 | 5 posts and articles | yes |
| F10 | 3 | 2 | 0 | 0 | 1 | 6 | 0 | 5 posts and articles | no |

### Trial dimensions

- Primary endpoint: Overall Survival (OS): F1 (23 shared claims), F2 (2 shared claims), F9 (4 shared claims)
- Secondary endpoints: F1 (1 shared claims), F2 (13 shared claims), F9 (2 shared claims)
- Population and setting: F2 (2 shared claims), F3 (4 shared claims), F5 (1 shared claims), F9 (1 shared claims)
- The comparison: F2 (6 shared claims), F3 (2 shared claims), F4 (3 shared claims), F5 (4 shared claims), F9 (1 shared claims)
- Safety and tolerability: F1 (9 shared claims), F9 (1 shared claims)
- Design and conduct: F1 (3 shared claims), F3 (5 shared claims), F5 (1 shared claims), F10 (1 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F3. Comparator criticism centers on evolving transplant/CAR-T eligibility and later treatment

A LinkedIn post asks how patients initially deemed unsuitable for transplantation could receive intensive treatment after progression.

Source: LinkedIn post, 2026-07-17.

### F2. The perceived efficacy signal is response durability, not the median PFS difference

A podcast discussion asks whether sustained control of lymphoma will translate into longer overall survival.

Source: podcast, 2026-06-15.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 10 | Titles free |
| Detailed analysis | 11 sections | Paid |
| Verified statements with short source quotes and links | 113 | Paid |
| Trial aspects mapped | 14 | Free |
| Sources with links | 19 | Counts free |
| Speaker attribution for cited voices | 13 | Paid |

## Trial aspects

14 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Overall Survival (OS) | discussed | 26 | 10 |
| Secondary endpoints | discussed | 15 | 8 |
| Population and setting | discussed | 10 | 7 |
| The comparison | discussed | 19 | 8 |
| Safety and tolerability | discussed | 9 | 4 |
| Design and conduct | discussed | 13 | 6 |
| CAR-T/transplant positioning and changing eligibility | discussed | 9 | 4 |
| Conditional monotherapy preference and combination alternatives | discussed | 17 | 4 |
| Cross-trial interpretation, comparator strength and information value | discussed | 6 | 3 |
| Outpatient delivery, infection prevention and supportive care | discussed | 14 | 3 |
| EPCORE NHL-1 and earlier bispecific evidence informing the R/R DLBCL choice | discussed | 11 | 3 |
| Sequencing, CD20 reassessment, cure and long-term uncertainty | discussed | 4 | 1 |
| Confirmatory evidence, regulatory interpretation and endpoint communication | discussed | 11 | 5 |
| Enrollment feasibility and nonclinical expectations | discussed | 5 | 4 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 50 | 14 |
| Bluesky threads | 8 | 0 |
| Podcasts | 3 | 3 |
| LinkedIn posts | 1 | 1 |
| YouTube | 1 | 1 |

- Screened window: 2020-11-14 to 2026-10-06
- Cited window: 2020-12-10 to 2026-10-06
- Retrieved: 2026-10-30

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
- Registry: NCT04628494 (https://clinicaltrials.gov/study/NCT04628494)
- Study IDs: GCT3013-05 · 2023-504830-23-00 · 2020-003016-27 · jRCT2021220017 (Japan Registry for Clinical Trials (jRCT)) · CTR20221558 (ChinaDrugTrials.org.cn) · MOH_2021-01-18_009672 (Clinical Research Site - mytrial) · NL75079.056.20 (CCMO (the Netherlands)) · 286972 (IRAS ID; UK Research Summaries Database)
- Sponsor: Genmab
- Collaborators: AbbVie
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Active, not recruiting
- Enrollment: 483 (actual)
- Start: 2021-01-13 (actual)
- Primary completion: 2025-10-13 (actual)
- Primary endpoint: Overall Survival (OS) (Up to approximately 5 years)
- Intervention: Epcoritamab (biological)
- Intervention: Investigator's Choice Chemotherapy (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Some clinician views in the sources used in this report are not yet captured as evidence in this edition.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 63 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The sources reviewed for this edition do not represent all HCP discussion. Remarks using unnamed references or less common variants may be missing, and several passages were not fully assessed for clinician views.
- No results publication or full protocol for NCT04628494 was among the sources reviewed. Many numerical, endpoint and regulatory descriptions are commentary restatements or second-hand accounts.
- The Pharma Closeout passages do not establish who delivered the words. Listed participants are not used to assign those views.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The a podcast podcast and YouTube versions contain the same exchange; parallel versions and reposts do not constitute additional independent clinical views.
- COVID-19, infection and subsequent-treatment explanations for OS remain interpretive. Unadjusted OS, COVID-19-censored curves and post hoc adjusted OS estimates are kept distinct.
- Safety percentages differ in their descriptions and certainty: fatal adverse events are not necessarily treatment-related deaths, a speaker's 17% mortality denominator is unspecified, and the study associated with the Nordea safety paragraph is unclear.
- The practical-care account is incomplete, particularly on first-full-dose setting, decisions during active infection, laboratory and immunoglobulin support, and assessment of new neurological symptoms. It should not be read as a complete treatment-delivery or treatment-holding framework.
- Earlier single-arm studies and separate combination trials inform the treatment question but are not EPCORE DLBCL-1 results or head-to-head evidence against CAR-T.
- FDA draft-guidance relays and proposed confirmatory implications are not treated as announced regulatory decisions.
- Not yet captured in this edition: a view on bispecific-based treatment versus chemotherapy in transplant-ineligible relapsed or refractory diffuse large B-cell lymphoma.
- Not yet captured in this edition: a view on bispecific combinations versus chemotherapy in second-line transplant-ineligible relapsed or refractory DLBCL.
- Not yet captured in this edition: a view on bispecific combination therapy versus chemotherapy in second-line relapsed or refractory diffuse large B-cell lymphoma.
- Not yet captured in this edition: a remark on clarifying the epcoritamab combination partner while CAR-T eligibility remains uncertain.
- Not yet captured in this edition: a view on distinguishing overall-population from second-line subgroup evidence when evaluating bispecific treatment in relapsed or refractory DLBCL.
- Not yet captured in this edition: a view on efficacy, safety and regulatory qualifications of alternative bispecific-containing regimens in relapsed or refractory DLBCL.
- Not yet captured in this edition: a remark on the combination partner and cellular-therapy eligibility in a related second-line epcoritamab comparison.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-31: current edition, corrected 2026-10-31
  - Correction 2026-10-31: Corrected to match the delivered report: the limitations; the sample findings; the report description.

Last checked for new commentary 2026-10-31. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (113 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (8 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/epcore-dlbcl-1-nct04628494
- Agents: POST https://www.erudio.com/api/orders with {"report": "epcore-dlbcl-1-nct04628494", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=epcore-dlbcl-1-04628494

## Cite

Erudio Health. EPCORE DLBCL-1 (NCT04628494): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 31, 2026. https://www.erudio.com/reports/epcore-dlbcl-1-nct04628494

## Machine access

- JSON: https://www.erudio.com/reports/epcore-dlbcl-1-nct04628494.json
- Markdown: https://www.erudio.com/reports/epcore-dlbcl-1-nct04628494.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "epcore-dlbcl-1-04628494"}`